Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.70 Consensus Target Price from Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $11.70.

Several research analysts have commented on CRDF shares. Jefferies Financial Group started coverage on Cardiff Oncology in a research report on Tuesday, June 24th. They set a “hold” rating and a $3.50 price target on the stock. HC Wainwright lifted their price target on Cardiff Oncology from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, May 9th. LADENBURG THALM/SH SH began coverage on Cardiff Oncology in a research report on Tuesday, July 8th. They set a “buy” rating and a $19.00 price target on the stock. Finally, William Blair reissued an “outperform” rating on shares of Cardiff Oncology in a report on Wednesday, June 18th.

Insiders Place Their Bets

In other Cardiff Oncology news, Director Gary W. Pace bought 15,000 shares of the stock in a transaction that occurred on Wednesday, July 30th. The shares were purchased at an average cost of $2.45 per share, for a total transaction of $36,750.00. Following the transaction, the director directly owned 1,345,676 shares in the company, valued at $3,296,906.20. The trade was a 1.13% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CRDF. SteelPeak Wealth LLC grew its holdings in shares of Cardiff Oncology by 23.2% during the second quarter. SteelPeak Wealth LLC now owns 22,800 shares of the company’s stock valued at $72,000 after buying an additional 4,300 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Cardiff Oncology during the fourth quarter valued at $25,000. Thoroughbred Financial Services LLC grew its holdings in shares of Cardiff Oncology by 43.8% during the fourth quarter. Thoroughbred Financial Services LLC now owns 19,614 shares of the company’s stock valued at $85,000 after buying an additional 5,970 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Cardiff Oncology by 12.8% during the fourth quarter. American Century Companies Inc. now owns 53,955 shares of the company’s stock valued at $234,000 after buying an additional 6,140 shares in the last quarter. Finally, Corebridge Financial Inc. grew its holdings in shares of Cardiff Oncology by 40.8% during the first quarter. Corebridge Financial Inc. now owns 28,555 shares of the company’s stock valued at $90,000 after buying an additional 8,277 shares in the last quarter. 16.29% of the stock is owned by institutional investors and hedge funds.

Cardiff Oncology Stock Down 4.9%

CRDF stock opened at $2.51 on Friday. The business has a 50 day moving average price of $3.58 and a 200 day moving average price of $3.49. The stock has a market cap of $166.99 million, a price-to-earnings ratio of -2.89 and a beta of 1.54. Cardiff Oncology has a fifty-two week low of $2.01 and a fifty-two week high of $5.64.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Tuesday, July 29th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The business had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.11 million. Cardiff Oncology had a negative return on equity of 77.94% and a negative net margin of 9,344.14%. As a group, sell-side analysts anticipate that Cardiff Oncology will post -0.99 EPS for the current year.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.